Anna Gisselsson
Directeur/Bestuurslid bij Moroxite F AB
Profiel
Anna Gisselsson is currently working as a Director at Moroxite F AB and as an Investment Manager at Almi Invest AB.
She has a graduate and doctorate degree from the Faculty of Engineering, Lund University.
Actieve functies van Anna Gisselsson
Bedrijven | Functie | Begin |
---|---|---|
Almi Invest AB
Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | Private Equity Investor | 01-11-2020 |
Moroxite F AB
Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures. | Directeur/Bestuurslid | - |
Opleiding van Anna Gisselsson
Faculty of Engineering, Lund University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Almi Invest AB
Almi Invest AB Investment ManagersFinance Almi Invest AB (Almi) is a Venture Capital subsidiary of ALMI Företagspartner AB, founded in 2009. The firm is headquartered in Stockholm, Sweden. | Finance |
Moroxite F AB
Moroxite F AB Miscellaneous Commercial ServicesCommercial Services Moroxite F AB has developed a regenerative medicine approach for fragility fractures, which improves implant anchorage and reduces fixation failures, re-operations, societal costs, and improves quality of life. The company is based in Lund, Sweden. The Swedish company has also developed an injectable platform for prolonged release of hydroxyapatite binding drugs in fragility fractures. | Commercial Services |